Bifidobacterium (mixed strains) has scientific evidence to support its use in the management of enteritis, particularly in infectious and antibiotic-associated enteritis. Bifidobacteria are a group of probiotic bacteria that are naturally found in the human gastrointestinal tract. Several clinical trials and meta-analyses have shown that supplementation with Bifidobacterium species can help restore the balance of intestinal microbiota, reduce inflammation, and enhance mucosal barrier function. In cases of infectious enteritis, such as rotavirus diarrhea in children, studies have demonstrated that probiotics containing Bifidobacterium can reduce the duration and severity of diarrhea. Similarly, for antibiotic-associated diarrhea, which can sometimes manifest as enteritis, Bifidobacterium supplementation has been found to decrease the risk and duration of symptoms.

Mechanistic studies indicate that Bifidobacterium exerts beneficial effects by producing short-chain fatty acids (such as acetate and lactate), which lower intestinal pH and inhibit the growth of pathogenic bacteria. They also modulate immune responses, promoting anti-inflammatory cytokines and supporting the integrity of the gut mucosal barrier. However, while the evidence is generally positive, the efficacy can depend on the strain used, the dosage, and the patient population. Most studies support adjunctive rather than primary therapy for enteritis. The overall evidence base rates as moderate (3/5) as there is consistent support from clinical studies, but more large-scale, high-quality randomized controlled trials are needed to establish optimal protocols.